Rebuilding the Lung
Rebuilding the Lung
批准号:
7871715
负责人:
Angela Panoskaltsis-Mortari
金额:
$20.49万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-04-01 至 2012-03-31
关键词:
3-DimensionalAdultAirAortaApplications GrantsBiological ModelsBiomedical EngineeringBioreactorsBloodBronchiolitisCell Differentiation processCell TherapyCell-Matrix JunctionCellsCharacteristicsChemicalsChronicChronic Obstructive Airway DiseaseClinical TrialsCultured CellsCystic FibrosisDataDevelopmentEndothelial CellsEndotheliumEnvironmentEnvironmental air flowEpithelialEpithelial CellsEpitheliumEvaluationExtracellular MatrixFetal LungGenerationsGoalsGrantGrowthGrowth FactorHamman-Rich syndromeHeadImplantInfusion proceduresInterstitial Lung DiseasesLiquid substanceLungLung TransplantationLung diseasesMesenchymal Stem CellsMusOrganOrgan DonorPatientsPatternPluripotent Bone Marrow Stem CellPluripotent Stem CellsPopulationPositioning AttributeProcessProtein C InhibitorProteinsPulmonary EmphysemaPumpRattusReportingRight ventricular structureRodentSourceStagingStem cellsStretchingStructure of parenchyma of lungSystemTACSTD2 geneTechnical ExpertiseTestingTimeTissuesTracheaTransplantationVascular Endotheliumcell growthexperiencefetalinjuredinterestlung basal segmentmortalitynovelprogenitorpublic health relevancepulmonary arterial hypertensionrepairedscaffoldsuccesstranslational study
中文摘要
描述(由申请人提供):我们的最终目标是利用去细胞化的肺作为肺祖细胞的天然三维(3-D)基质基础重建肺。肺移植通常是不可逆结构性肺损伤患者的唯一选择,但由于缺乏肺器官供体和慢性排斥反应等主要障碍,阻碍了肺移植。人工支架不能复制肺细胞外基质的分支或组成、排列和伸展。我们将专注于利用通风、去细胞化的全肺作为天然3d基质重建肺,并用具有肺上皮和内皮祖细胞潜力的细胞重新填充。我们有数据表明,即使在长时间通气后,啮齿动物的肺也可以成功地去细胞化,同时保持细胞外基质在正确的地理空间分支模式。成人和胎儿肺细胞可以成功地输注和培养在脱细胞,通气肺。我们假设,在适当的生长条件下,假定的祖细胞将重新上皮化和再内皮化基质,并产生肺细胞特征的蛋白质。我们还预计细胞输入的时间、生长因子和发育阶段适当的通气伸展对这一过程至关重要。在Aim 1中,我们将确定假定的肺祖细胞群,如诱导多能细胞(iPS)细胞、bm衍生细胞和EpCAM+肺衍生细胞,是否会在我们新的“肺生物反应器”系统中通风、脱细胞、全肺基质环境中生长和分化。我们将比较单独和联合培养这些细胞在成人和胎儿肺制备的脱细胞基质中的效果。在Aim 2中,我们将使用血液外生内皮细胞(BOECs)和Aim 1中最好的细胞来确定上皮和内皮是否可以再细胞化。我们在进行这些研究方面处于独特的地位。我们拥有独特的模型系统和经验丰富的合作者,他们为这项拨款申请提供新颖的细胞,关键的专业知识和建议。
英文摘要
DESCRIPTION (provided by applicant): Our ultimate goal is to rebuild the lung using decellularized lung as a natural 3-dimensional (3-D) matrix base for lung progenitor cells. Lung transplantation is usually the only option for patients with irreversible structural lung damage but is hindered by major obstacles such as lack of lung organ donors and chronic rejection. Artificial scaffolds cannot replicate the branching or the composition, arrangement and stretch of the extracellular matrix of the lung. We will focus on rebuilding the lung using ventilated, decellularized whole lungs as a natural 3-D matrix and repopulate it with cells having potential as lung epithelial and endothelial progenitors. We have data that rodent lungs can successfully be decellularized while maintaining extracellular matrix in the correct geospatial branching pattern even after prolonged ventilation. Adult and fetal lung cells can successfully be infused and cultured in decellularized, ventilated lungs. We hypothesize that, given the right growth conditions, putative progenitors will re-epithelialize and re-endothelialize the matrix and produce proteins characteristic of lung cells. We also expect that timing of cell input, growth factors and developmental stage-appropriate ventilatory stretch will be critical to this process. In Aim 1, we will determine if putative lung progenitor cell populations such as induced pluripotent (iPS) cells, BM-derived cells and EpCAM+ lung-derived cells, will grow and differentiate in the setting of a ventilated, decellularized, whole lung matrix in our new "lung bioreactor" system. We will compare culturing these cells, alone and in combination, in decellularized matrices prepared from adult and fetal lungs. In Aim 2, we will determine if both epithelium and endothelium can be recellularized using blood outgrowth endothelial cells (BOECs) and the best cells from Aim 1. We are in a unique position to perform these studies. We have a unique model system and highly experienced collaborators who provide novel cells, critical expertise and advice for this grant application.
PUBLIC HEALTH RELEVANCE: Lung transplantation is usually the only option for patients with irreversible structural lung damage but is hindered by major obstacles such as lack of lung organ donors and chronic rejection. We will focus on rebuilding the lung using ventilated, decellularized whole rodent lungs as a natural 3-D matrix and repopulate it with cells having the potential to grow into lung tissue and produce proteins characteristic of lung cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Rejuvenation of the Lung
-
批准号:9224388
-
项目类别:
-
资助金额:$15.28万
-
财政年份:2017
-
负责人:Angela Panoskaltsis-Mortari
-
依托单位:
Overcoming Barriers to Bioengineering 3-D Human Lung
-
批准号:8478182
-
项目类别:
-
资助金额:$70.56万
-
财政年份:2011
-
负责人:Angela Panoskaltsis-Mortari
-
依托单位:
Overcoming Barriers to Bioengineering 3-D Human Lung
-
批准号:8705572
-
项目类别:
-
资助金额:$71.1万
-
财政年份:2011
-
负责人:Angela Panoskaltsis-Mortari
-
依托单位:
Overcoming Barriers to Bioengineering 3-D Human Lung
-
批准号:8135140
-
项目类别:
-
资助金额:$69.04万
-
财政年份:2011
-
负责人:Angela Panoskaltsis-Mortari
-
依托单位:
Overcoming Barriers to Bioengineering 3-D Human Lung
-
批准号:8328582
-
项目类别:
-
资助金额:$70.11万
-
财政年份:2011
-
负责人:Angela Panoskaltsis-Mortari
-
依托单位:
Overcoming Barriers to Bioengineering 3-D Human Lung
-
批准号:8527105
-
项目类别:
-
资助金额:$4.86万
-
财政年份:2011
-
负责人:Angela Panoskaltsis-Mortari
-
依托单位:
Overcoming Barriers to Bioengineering 3-D Human Lung
-
批准号:8885367
-
项目类别:
-
资助金额:$15.59万
-
财政年份:2011
-
负责人:Angela Panoskaltsis-Mortari
-
依托单位:
Overcoming Barriers to Bioengineering 3-D Human Lung
-
批准号:8842817
-
项目类别:
-
资助金额:$3.02万
-
财政年份:2011
-
负责人:Angela Panoskaltsis-Mortari
-
依托单位:
Rebuilding the Lung
-
批准号:8044042
-
项目类别:
-
资助金额:$18.88万
-
财政年份:2010
-
负责人:Angela Panoskaltsis-Mortari
-
依托单位:
Post BMT Lung Injury Pathophysiology
-
批准号:7564822
-
项目类别:
-
资助金额:$35.44万
-
财政年份:1995
-
负责人:Angela Panoskaltsis-Mortari
-
依托单位:
海外基金